Logotype for Immunovant Inc

Immunovant (IMVT) investor relations material

Immunovant Corporate Presentation summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Immunovant Inc
Corporate Presentation summary4 Sep, 2025

Strategic focus and product pipeline

  • Pursuing a broad anti-FcRn strategy with IMVT-1402, targeting autoantibody-driven diseases and aiming for best-in-class efficacy and convenience across multiple indications.

  • IMVT-1402 is positioned as a potential first- and best-in-class product, with robust IgG lowering, favorable safety, and simple autoinjector delivery.

  • Ongoing and planned registrational trials span Graves' disease, Sjögren's disease, difficult-to-treat rheumatoid arthritis, CIDP, MG, and CLE, addressing over 600,000 US patients.

  • Strong patent protection extends to 2043, supporting long-term commercial potential.

  • Cash balance of ~$600 million as of June 2025 provides runway through key clinical readouts.

Clinical evidence and differentiation

  • Deeper IgG reduction with anti-FcRn therapy correlates with improved clinical outcomes across multiple autoimmune indications.

  • IMVT-1402 and batoclimab demonstrate best-in-class IgG reductions (up to ~80%), outperforming competitors in cross-trial comparisons.

  • Phase 3 batoclimab data in MG showed highest MG-ADL reduction and minimal symptom expression rates among global trials.

  • Batoclimab CIDP Phase 2b data showed 84% response rate in patients with ≥70% IgG reduction, informing IMVT-1402 trial design.

  • IMVT-1402 is delivered via a user-friendly, market-proven autoinjector, supporting at-home or HCP administration.

Market opportunity and unmet need

  • Large total addressable market with 20+ indications in development across the anti-FcRn class, including neurology, endocrinology, rheumatology, dermatology, and renal diseases.

  • Graves' disease: ~880K US prevalence, with ~330K relapsed, uncontrolled, or intolerant to ATDs, and ~20K annual incident second-line patients.

  • Myasthenia gravis: 59K–116K US patients, with 35% not well-controlled on standard of care and high rates of residual symptoms on current therapies.

  • CIDP: 58K US patients, with 30–50% inadequately controlled on existing therapies and high demand for improved response and convenience.

  • D2T RA: 5–20% of 1.5M US RA patients are difficult-to-treat, representing a 70K addressable population needing new options.

  • Sjögren's disease: 290K US prevalence, no approved therapies, and 90K addressable patients with moderate-to-severe disease.

  • CLE: 153K US prevalence for SCLE and CCLE, with up to 50% non-responders to current therapies and no novel treatments in over 50 years.

Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.

Next Immunovant earnings date

Logotype for Immunovant Inc
Q2 20267 Nov, 2025
Your earnings 
season toolkit.
Download
Free on both iOS & Android.

Next Immunovant earnings date

Logotype for Immunovant Inc
Q2 20267 Nov, 2025

The essential earnings season companion

The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.

Live calls and transcripts

Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.

Find what you need faster

Search for any keyword across all transcripts simultaneously.

Easily store key findings

Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Your watchlist. Your dashboard.

Follow the companies that matter to you. Get a personalized feed with real-time updates.

Be the first to know

Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.

Consensus estimates

Access analyst consensus estimates, valuation multiples, and revenue segments splits.

All IR material in one place

The easiest way to stay updated during earnings season.

Global coverage

All events from public companies. Live and recorded.

Just click and listen

No webcast links. No manual registrations.

Research anytime, anywhere

Built for professionals. Loved by everyone. Try our free mobile app.

excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com

Frequently asked questions

Immunovant, Inc. (IMVT) is a clinical-stage biopharmaceutical company focused on the development of innovative treatments for patients with autoimmune diseases. Leveraging advanced anti-FcRn technology, Immunovant aims to create targeted therapies designed to address the complex and variable nature of autoimmune conditions. The company's approach is centered on improving the lives of patients by developing treatments that can potentially modify or halt the autoimmune response without compromising the immune system's ability to fight infections. Immunovant's research pipeline includes promising investigational products that embody the company's commitment to advancing the field of immunology and providing new options for individuals affected by autoimmune diseases. The company is headquartered in New York, NY, and its shares are listed on the Nasdaq.

Quartr provides global coverage of all investor relation material from public companies.

  • Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.

  • Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.

  • Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.

Yes, the Quartr mobile app is free on both iOS and Android.

Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.

Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.

Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.

Explore our global coverage